TCGA-AQ-A0Y5-01A-11R-A14M-07
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
- overall_survival_months
- 6
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.510
- ANGIOGENESIS+0.480
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.480
- HEDGEHOG_SIGNALING+0.470
- HYPOXIA+0.420
- UV_RESPONSE_DN+0.390
- ANDROGEN_RESPONSE+0.360
- MTORC1_SIGNALING+0.350
- PANCREAS_BETA_CELLS+0.350
- ADIPOGENESIS+0.250
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.490
- E2F_TARGETS-0.410
- MYC_TARGETS_V2-0.400
- G2M_CHECKPOINT-0.360
- INTERFERON_GAMMA_RESPONSE-0.330
- ALLOGRAFT_REJECTION-0.300
- DNA_REPAIR-0.290
- WNT_BETA_CATENIN_SIGNALING-0.230
- MITOTIC_SPINDLE-0.170
- APICAL_SURFACE-0.150
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8518340 | — | F | 0.835 |
| 2 | SRR8518315 | — | F | 0.818 |
| 3 | SRR8518181 | — | F | 0.814 |
| 4 | 20060030.TNBC | — | F | 0.812 |
| 5 | TCGA-CV-6935-01A-11R-1915-07 | — | — | 0.803 |
| 6 | SRR8518325 | — | F | 0.798 |
| 7 | SRR8613755 | — | F | 0.791 |
| 8 | TCGA-E2-A152-01A-11R-A12D-07 | — | C | 0.789 |
| 9 | TCGA-A2-A04W-01A-31R-A115-07 | — | C | 0.789 |
| 10 | TCGA-AR-A1AN-01A-11R-A12P-07 | — | A | 0.788 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.510 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.480 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.480 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.470 | Inavolisib | — uncovered |
| HYPOXIA | 0.420 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.390 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.360 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.350 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.350 | Cobimetinib | — uncovered |
| ADIPOGENESIS | 0.250 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.250 | Inavolisib | — uncovered |
| MYOGENESIS | 0.250 | Inavolisib | — uncovered |
| COAGULATION | 0.240 | Binimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.240 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.230 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.220 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.200 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.160 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.150 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.140 | Idelalisib | — uncovered |